Issue of Share Options/PDMR Shareholdings

Diaceutics PLC

(“Diaceutics” or the “Company”)

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of £0.002 each in the Company (“Share Options”) to certain Directors, members of the Company’s senior management team and other key staff, pursuant to the Company’s Employee Share Option Plan (“ESOP”). These awards are made in accordance with the Company’s long term incentive plan.

Share Options were granted as follows:

Name    Number of Share Options granted    Total no. of ordinary shares under option post grant    % of existing issued share capital    Effective Grant date
Peter Keeling, CEO    73,542    253,542    0.30%    1 April 2021
Philip White, CFO    64,154    244,154    0.29%    1 April 2021
Ryan Keeling, CIO    64,154    244,154    0.29%    1 April 2021
Damian Thornton, COO and PDMR    64,062                166,766    0.20%    1 April 2021
Jordan Clark, CCO and PDMR    46,003    122,117    0.15%    1 April 2021
Susanne Munksted, PDMR    45,475    116,147    0.14%    1 April 2021
Other employees (36 persons)    534,581    869,811    1.03%       1 April 2021


The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the “Performance Period”), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, measured using the average mid-market closing share price in the month immediately before the end of the Performance Period, plus any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 102.67p, being the average mid-market closing share price in the three days prior to 1 April 2021, when the options were issued. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 2,016,687, representing approximately 2.4% of its current issued share capital of 84,063,923.

Enquiries

Diaceutics PLC

Peter Keeling, Chief Executive Officer

Philip White, Chief Financial Officer

 
Cenkos Securities plc (Nominated adviser and broker)

Callum Davidson / Giles Balleny

Michael Johnson (Sales)

+44 (0)207 397 8900

Walbrook PR

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893